Pay in 4 interest-free payments of $6.97 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
JAMA Network Improved diabetes remission, better glycemic control (less reliance on medications) in longer term trials
However, 13-week Phase 2 data in 125 patients cannot be meaningfully compared to 68-week Phase 3 data in 1,961 patients
We work together with your diabetes care team to determine whether continuing, modifying, or changing your medication is the safest choice based on your specific situation
More specifically, it seems to be a combination of: documenting the medical needs of patients (probably through intake forms) who are experiencing or have experienced nausea, vomiting, or other drug tolerance-related issues associated with GLP-1s (which are discussed in this Hims paper), and providing personalized compounded semaglutide in doses outside the 10% threshold to address those documented medical needs
What if I cannot afford the approved version
Goldstein, R
